Deciphering the role of Hippo pathway in lung cancer

Ghafouri‐Fard, Soudeh; Poornajaf, Yadollah; Hussen, Bashdar Mahmud; Avval, Shiva Tavakkoli; Taheri, Mohammad; Mokhtari, Majid

doi:10.1016/j.prp.2023.154339

Cited by 8 publications

(2 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Hippo pathway has been widely studied as a target for tumor treatment. At present, it is known that the anticancer effects of gallic acid, icotinib hydrochloride, curcumin, ginsenoside Rg3, cryptotanshinone, nitidine chloride, cucurbitacin E, erlotinib, doxorubicin, sophoridine, cisplatin, and verteporfin are mediated by regulation of the Hippo pathway ( Ghafouri-Fard et al, 2023 ). However, these drugs promote tumor cell apoptosis by damaging mitochondrial function, inhibiting cell viability, and causing cardiotoxicity ( She et al, 2023 ).…”

Section: Clinical Applications and Prospectsmentioning

confidence: 99%

Non-coding RNAs as regulators of the Hippo pathway in cardiac development and cardiovascular disease

Song,

Wang,

Liu

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Cardiovascular diseases pose a serious threat to human health. The onset of cardiovascular diseases involves the comprehensive effects of multiple genes and environmental factors, and multiple signaling pathways are involved in regulating the occurrence and development of cardiovascular diseases. The Hippo pathway is a highly conserved signaling pathway involved in the regulation of cell proliferation, apoptosis, and differentiation. Recently, it has been widely studied in the fields of cardiovascular disease, cancer, and cell regeneration. Non-coding RNA (ncRNAs), which are important small molecules for the regulation of gene expression in cells, can directly target genes and have diverse regulatory functions. Recent studies have found that ncRNAs interact with Hippo pathway components to regulate myocardial fibrosis, cardiomyocyte proliferation, apoptosis, and hypertrophy and play an important role in cardiovascular disease. In this review, we describe the mode of action of ncRNAs in regulating the Hippo pathway, provide new ideas for further research, and identify molecules involved in the mechanism of action of ncRNAs and the Hippo pathway as potential therapeutic targets, with the aim of finding new modes of action for the treatment and prevention of cardiovascular diseases.

show abstract

Section: Clinical Applications and Prospectsmentioning

confidence: 99%

Non-coding RNAs as regulators of the Hippo pathway in cardiac development and cardiovascular disease

Song,

Wang,

Liu

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…The combination of Cur and Er has demonstrated low dose administration, high efficacy, minimal side effects, and the ability to prevent or reverse multidrug resistance [ 8 – 11 ]. Several studies suggest that Cur can inhibit Er resistance by maintaining ikappa-B expression levels and downregulating PI3K expression in the EGFR downstream signaling pathway, thereby promoting the release of apoptotic proteins caspase-3 and caspase-9 [ 12 , 13 ]. However, challenges remain in the clinical translation of this combination therapy, including poor water solubility, a short half-life, non-targeting, and pharmacokinetic hindrances [ 14 , 15 ].…”

Section: Introductionmentioning

confidence: 99%

Targeted co-delivery of curcumin and erlotinib by MoS2 nanosheets for the combination of synergetic chemotherapy and photothermal therapy of lung cancer

Chen,

Wei,

Zheng

et al. 2023

J Nanobiotechnol

View full text Add to dashboard Cite

Background Curcumin (Cur), a bioactive component of Chinese traditional medicine, has demonstrated inhibitory properties against cancer cell proliferation while synergistically enhancing the anticancer efficacy of erlotinib (Er). However, the individual limitations of both drugs, including poor aqueous solubility, lack of targeting ability, short half-life, etc., and their distinct pharmacokinetic profiles mitigate or eliminate their combined antitumor potential. Results In this study, we developed a molybdenum disulfide (MoS2)-based delivery system, functionalized with polyethylene glycol (PEG) and biotin, and co-loaded with Cur and Er, to achieve efficient cancer therapy. The MoS2-PEG-Biotin-Cur/Er system effectively converted near-infrared (NIR) light into heat, thereby inducing direct photothermal ablation of cancer cells and promoting controlled release of Cur and Er. Biotin-mediated tumor targeting facilitated the selective accumulation of MoS2-PEG-Biotin-Cur/Er at the tumor site, thus enhancing the synergistic antitumor effects of Cur and Er. Remarkably, MoS2-PEG-Biotin-Cur/Er achieved the combination of synergistic chemotherapy and photothermal therapy (PTT) upon NIR irradiation, effectively suppressing lung cancer cell proliferation and inhabiting tumor growth in vivo. Conclusions The as-synthesized MoS2-PEG-Biotin-Cur/Er, featuring high targeting ability, NIR light-responsive drug release, and the integration of synergistic chemotherapy and PTT, may provide a promising strategy for the treatment of lung cancer in clinical practice. Graphical Abstract

show abstract

Comparison of gene mutation profile in different lung adenocarcinoma subtypes by targeted next-generation sequencing

Zhang,

Dong,

Pan

et al. 2023

Med Oncol

View full text Add to dashboard Cite

Deciphering the role of Hippo pathway in lung cancer

Cited by 8 publications

References 56 publications

Non-coding RNAs as regulators of the Hippo pathway in cardiac development and cardiovascular disease

Non-coding RNAs as regulators of the Hippo pathway in cardiac development and cardiovascular disease

Targeted co-delivery of curcumin and erlotinib by MoS2 nanosheets for the combination of synergetic chemotherapy and photothermal therapy of lung cancer

Comparison of gene mutation profile in different lung adenocarcinoma subtypes by targeted next-generation sequencing

Contact Info

Product

Resources

About